Handelsbanken Fonder AB Boosts Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

Handelsbanken Fonder AB raised its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) by 11.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,800 shares of the company’s stock after buying an additional 1,100 shares during the period. Handelsbanken Fonder AB’s holdings in Keros Therapeutics were worth $171,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after acquiring an additional 280 shares in the last quarter. AlphaCentric Advisors LLC purchased a new position in Keros Therapeutics in the third quarter valued at approximately $465,000. Victory Capital Management Inc. acquired a new stake in Keros Therapeutics during the third quarter worth approximately $216,000. KBC Group NV raised its holdings in Keros Therapeutics by 52.0% during the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after purchasing an additional 432 shares in the last quarter. Finally, LMR Partners LLP purchased a new stake in shares of Keros Therapeutics during the 3rd quarter worth approximately $213,000. 71.56% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on KROS shares. TD Cowen downgraded shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. BTIG Research lowered Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, December 12th. Oppenheimer reduced their target price on Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a report on Thursday, January 16th. Guggenheim reissued a “neutral” rating on shares of Keros Therapeutics in a research report on Friday, January 17th. Finally, Wells Fargo & Company cut their price target on Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, February 27th. Six research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, Keros Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.33.

Keros Therapeutics Trading Up 0.2 %

Keros Therapeutics stock opened at $11.10 on Tuesday. The stock has a 50 day moving average of $12.40 and a two-hundred day moving average of $39.25. Keros Therapeutics, Inc. has a twelve month low of $9.77 and a twelve month high of $72.37. The stock has a market capitalization of $449.63 million, a price-to-earnings ratio of -2.13 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, topping the consensus estimate of ($1.36) by $0.22. The firm had revenue of $3.04 million during the quarter, compared to the consensus estimate of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. Equities analysts predict that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.